Mid-stage study of RedHill Biopharma's opaganib in COVID-19 to continue unchanged
Oct. 7, 2020 12:07 PM ET|About: RedHill Biopharma Ltd. (RDHL)|By: Vandana Singh, SA News Editor
Independent Safety Monitoring Committee has completed second pre-scheduled safety review for RedHill Biopharma's (RDHL +4.1%) opaganib (Yeliva, ABC294640) U.S. Phase 2 study, in patients hospitalized with severe COVID-19 pneumonia, and recommended that the study continue unmodified.
The recommendation is based on an unblinded analysis of safety data from the first 24 patients treated in the study for at least seven days. The study is 75% enrolled.
The U.S. Phase 2 study looks to complete enrollment this month, with data expected to follow before the end of this year.
In parallel, the global Phase 2/3 study with opaganib in patients with severe COVID-19 pneumonia is on track to enroll up to 270 patients by the end of the year.
AI
Market Data 
Markets 
